XML 104 R86.htm IDEA: XBRL DOCUMENT v3.25.0.1
Subsequent Events (Additional Information) (Details) - USD ($)
$ in Millions
Feb. 23, 2025
Feb. 10, 2025
Dec. 31, 2024
Dec. 31, 2023
Subsequent Event [Line Items]        
Common stock shares outstanding     12,197,615 359,569
Subsequent event [Member]        
Subsequent Event [Line Items]        
Payment Related to Severance Cost   $ 1.1    
Number of common stock underlying shares 1,904,998      
Exercise of call option description On March 1, 2025, Oxford Biomedica (US), Inc. exercised its option to cause the Company to sell and transfer to Oxford Biomedica (US), Inc. all of the Company’s equity ownership interest in OXB (US) LLC. The sale price is based on a formula using the Company's pro rata share of OXB (US) LLC (10%), times a predetermined multiple of revenue for the immediately preceding 12-month period increased by OXB (US) LLC's cash balance and decreased by OXB (US) LLC's debt balance as of the exercise date.